# Vertex Pharmaceuticals Incorporated – Consensus ‘buy’ rating and -7.2% Downside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-consensus-buy-rating-and-7.2-downside-potential/4121136292
- Published: 2023-12-15T13:53:37+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) have now 25 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between $463.02 
and $300.96 and has a mean target at $375.86. Given that the stocks previous close
was at $405.07 this now indicates there is a potential downside of -7.2%. The 50
day MA is $362.34 and the 200 day MA is $343.02. The total market capitalization
for the company now stands at 104.77B. The stock price is currently at: $406.60 
USD

 The potential market cap would be $97,218,559,782 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 30.48, revenue per share of $37.49
and a 14.34% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on:
